The stock of Pliant Therapeutics Inc (PLRX) has seen a 7.96% increase in the past week, with a 26.90% gain in the past month, and a 14.54% flourish in the past quarter. The volatility ratio for the week is 5.34%, and the volatility levels for the past 30 days are at 5.22% for PLRX. The simple moving average for the past 20 days is 12.39% for PLRX’s stock, with a -6.86% simple moving average for the past 200 days.
Is It Worth Investing in Pliant Therapeutics Inc (NASDAQ: PLRX) Right Now?
The stock has a 36-month beta value of 1.13. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PLRX is 52.89M, and at present, short sellers hold a 13.16% of that float. On July 29, 2024, the average trading volume of PLRX was 591.05K shares.
PLRX) stock’s latest price update
The stock of Pliant Therapeutics Inc (NASDAQ: PLRX) has increased by 1.18 when compared to last closing price of 13.37.Despite this, the company has seen a gain of 7.96% in its stock price over the last five trading days. investorplace.com reported 2024-06-24 that Fundamentally, the biotechnology sphere enjoys a powerful catalyst: wealth without health means nothing. Yes, it’s important to save money and invest for the future.
Analysts’ Opinion of PLRX
Many brokerage firms have already submitted their reports for PLRX stocks, with Wells Fargo repeating the rating for PLRX by listing it as a “Overweight.” The predicted price for PLRX in the upcoming period, according to Wells Fargo is $41 based on the research report published on December 08, 2023 of the previous year 2023.
Canaccord Genuity, on the other hand, stated in their research note that they expect to see PLRX reach a price target of $48. The rating they have provided for PLRX stocks is “Buy” according to the report published on May 18th, 2023.
Robert W. Baird gave a rating of “Outperform” to PLRX, setting the target price at $44 in the report published on April 13th of the previous year.
PLRX Trading at 10.65% from the 50-Day Moving Average
After a stumble in the market that brought PLRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.13% of loss for the given period.
Volatility was left at 5.22%, however, over the last 30 days, the volatility rate increased by 5.34%, as shares surge +26.60% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.39% lower at present.
During the last 5 trading sessions, PLRX rose by +8.62%, which changed the moving average for the period of 200-days by -21.28% in comparison to the 20-day moving average, which settled at $12.18. In addition, Pliant Therapeutics Inc saw -25.30% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PLRX starting from Coulie Bernard, who sale 38,710 shares at the price of $11.56 back on Jul 10 ’24. After this action, Coulie Bernard now owns 482,936 shares of Pliant Therapeutics Inc, valued at $447,488 using the latest closing price.
Lefebvre Eric, the Chief Medical Officer of Pliant Therapeutics Inc, sale 12,319 shares at $11.56 during a trade that took place back on Jul 10 ’24, which means that Lefebvre Eric is holding 213,052 shares at $142,408 based on the most recent closing price.
Stock Fundamentals for PLRX
Current profitability levels for the company are sitting at:
- -38.22 for the present operating margin
- 0.39 for the gross margin
The net margin for Pliant Therapeutics Inc stands at -33.56. The total capital return value is set at -0.4. Equity return is now at value -34.17, with -30.50 for asset returns.
Based on Pliant Therapeutics Inc (PLRX), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -3.78. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -25.58.
Currently, EBITDA for the company is -182.3 million with net debt to EBITDA at 0.32. When we switch over and look at the enterprise to sales, we see a ratio of 149.85. The receivables turnover for the company is 2.2for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 16.12.
Conclusion
To sum up, Pliant Therapeutics Inc (PLRX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
